)
Edge6 Feb 2026
SharkNinja: Viral by Design
How SharkNinja built a repeatable growth engine, turning overlooked appliance categories into global brands through consumer insight and iteration.
InflaRx
InflaRx (IFRX) investor relations material
InflaRx Guggenheim Securities Emerging Outlook: Biotech Summit 2026 summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Guggenheim Securities Emerging Outlook: Biotech Summit 2026 summary11 Feb, 2026
Key product updates and differentiation
Izicopan, an oral C5aR antagonist, shows higher bioavailability, faster onset, and lower CYP3A4 inhibition compared to avacopan, suggesting improved safety and efficacy profiles.
No hepatotoxicity observed in approximately 200 patients treated with izicopan, even at high doses, supporting a clean safety profile.
Izicopan’s rapid achievement of steady-state plasma levels allows for lower dosing and potentially better patient outcomes.
The molecule’s lower risk of drug-drug interactions is attributed to significantly reduced CYP3A4 inhibition.
If avacopan is withdrawn from the market, izicopan could quickly capitalize on the opportunity due to its differentiated profile.
Clinical development and trial results
Proof-of-concept studies in hidradenitis suppurativa (HS) and chronic spontaneous urticaria (CSU) showed encouraging efficacy signals, especially in reducing draining tunnels and pain in HS.
Four-week basket study in HS demonstrated responses comparable or superior to other phase II/III HS trials, despite being non-placebo-controlled.
Long-term toxicology data now supports indefinite dosing, enabling progression to phase IIB trials.
Additional PK simulations and regulatory discussions are ongoing to finalize dosing and trial design for the next phase.
Phase IIB study is required before moving to pivotal trials in HS.
Strategic focus and pipeline outlook
HS remains the primary focus, but CSU is also under consideration for further development, especially in severe patient subsets.
Expansion into other autoimmune indications is possible, with future updates expected at the upcoming Capital Markets Day.
Commercial differentiation in HS will rely on biologic-like efficacy, safety, and unique benefits such as draining tunnel reduction.
Regulatory discussions are ongoing to define endpoints that reflect clinical benefits beyond standard HiSCR measures.
Partnerships may be pursued to expand into additional indications, depending on resources.
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next InflaRx earnings date
Oppenheimer 36th Annual Healthcare Life Sciences Conference25 Feb, 2026
InflaRx
Next InflaRx earnings date
Oppenheimer 36th Annual Healthcare Life Sciences Conference25 Feb, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
InflaRx N.V. is a clinical-stage biopharmaceutical company engaged in the discovery and development of drugs that inhibit the activation of the complement system, particularly targeting the C5a component, a potent inflammatory mediator. This focus addresses various autoimmune and other inflammatory diseases. The company's leading product candidate, vilobelimab, is a first-in-class anti-C5a monoclonal antibody with multiple clinical applications, including for diseases like hidradenitis suppurativa and cutaneous squamous cell carcinoma. The company is headquartered in Jena, Germany, and its shares are listed on the NASDAQ.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage